Publicação
Doença por vírus Ébola
| Resumo: | The Ebola virus disease (EVD) or Ebola virus hemorrhagic fever (EVHF) affects man and other non-human primates and was first identified in Sudan and in the Democratic Republic of Congo, evolving by outbreaks in tropical regions of sub-Saharan Africa. Currently, the largest one, ongoing since December 2013, is affecting part of West Africa, as Guinea Conakry, Sierra Leone, Liberia and Nigeria. The virus is transmitted by direct contact with the blood or other body fluids of the infected animal or man, not being proven the transmission by air. After an incubation period of two to three weeks, it will begin a clinical framework of high fever, headache, mioartralgia, odynophagia, abdominal pain, vomiting, diarrhea, rash, and internal and external bleeding, accompanied by anemia, leukopenia, thrombocytopenia and changes in liver, kidney and clotting function. The diagnosis is made by the detection of viral antibodies, viral RNA or by the isolation of virus in blood or in other body fluids, and given the nonspecific symptoms of Ebola virus disease, the differential diagnosis is made in situations with an identical clinical framework, such as malaria, cholera and other viral hemorrhagic fevers, which are endemic in those regions. In the absence of a specific therapeutic for this disease, the treatment is supportive, and due to the very high mortality rate (between 50% to 90%), all efforts are being made towards development of a vaccine. |
|---|---|
| Autores principais: | Castanheira, Daniel Neves Correia |
| Assunto: | Vírus Ébola Doença pelo vírus Ébola Vacinas contra Ébola |
| Ano: | 2015 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso restrito |
| Instituição associada: | Universidade de Lisboa |
| Idioma: | português |
| Origem: | Repositório da Universidade de Lisboa |
| Resumo: | The Ebola virus disease (EVD) or Ebola virus hemorrhagic fever (EVHF) affects man and other non-human primates and was first identified in Sudan and in the Democratic Republic of Congo, evolving by outbreaks in tropical regions of sub-Saharan Africa. Currently, the largest one, ongoing since December 2013, is affecting part of West Africa, as Guinea Conakry, Sierra Leone, Liberia and Nigeria. The virus is transmitted by direct contact with the blood or other body fluids of the infected animal or man, not being proven the transmission by air. After an incubation period of two to three weeks, it will begin a clinical framework of high fever, headache, mioartralgia, odynophagia, abdominal pain, vomiting, diarrhea, rash, and internal and external bleeding, accompanied by anemia, leukopenia, thrombocytopenia and changes in liver, kidney and clotting function. The diagnosis is made by the detection of viral antibodies, viral RNA or by the isolation of virus in blood or in other body fluids, and given the nonspecific symptoms of Ebola virus disease, the differential diagnosis is made in situations with an identical clinical framework, such as malaria, cholera and other viral hemorrhagic fevers, which are endemic in those regions. In the absence of a specific therapeutic for this disease, the treatment is supportive, and due to the very high mortality rate (between 50% to 90%), all efforts are being made towards development of a vaccine. |
|---|